维普期刊资源整合服务平台（V6.5）

46篇 您的检索式：作者名="Gordon AN"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial显示文摘	Kris V Kowdley Eric Lawitz Israel Crespo Tarek Hassanein Mitchell N Davis Michael DeMicco David E Bernstein Nezam Afdhal John M Vierling Stuart C Gordon Jane K Anderson Robert H Hyland Hadas Dvory-Sobol Di An Robert G Hindes Efsevia Albanis William T Symo	2013	The Lancet2013，，9883：	3
2	Sarcoma botryoid of the cer-vix:excision followed by adjuvant chemotherapy for preservation of reproductive function显示文摘	Gordon AN Montag TW	1990	Gynecol Oncol1990，36，：	1
3	Sarcoma botryoid of the cervix: excision followed by adjuvant chemotherapy for preservation of reproductive function显示文摘	Gordon AN Montag TW	1990	Gynecol Oncol1990，36，1：	1
4	Recurrent epithelial ovarian carcinoma:A randomized phase Ⅲ study of pegylated liposomal doxorubicin Versus topotecan显示文摘	Gordon AN Fleagle JT Guthrie D	2001	J clin Oncol2001，19，14：	1
5	CA 125 and tumorspecific T-cell response correlates with prolonged survival in oregovomab-treated recurrent ovarian cancer patients显示文摘	Gordon AN Schultes BC Gallion H	2004	Gynecol Oncol2004，94，2：	1
6	Long-term survival advantange forwomen treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory ep ithelial ovarian cancer显示文摘	Gordon AN TondaM Sun S	2004	Gynecol Oncol2004，95，1：	1
7	Recurrent epithelial ovarian carcinoma:a randomized phase III study of pegylated liposomal doxorubicin versus topotecan显示文摘	Gordon AN Fleagle JT Guthrie D	2001	J Clin Oncol2001，19，14：	1
8	Long - term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer 显示文摘	Gordon AN Tonda M Sun S	2004	Gynecol Oncol2004，95，1：	1
9	Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment显示文摘	Andersen AN Witjes H Gordon K	2011	Hum Reprod2011，26，12：	1
10	Recurrent epithelial ovarian carcinoma; a randomized phase Ⅲ study of pegylated liposomal doxorubicin resus topotecan显示文摘	Gordon AN Fleagle JT GuthrieD PG etal	2001	J Clin Oncol2001，19，14：	1
11	Recurrent epithelial ovarian carcinoma:a randomized phase Ⅲ study of pegylated 1-iposomal doxorubicin versus topotecan显示文摘	Gordon AN Tleagle JT Guthrie D	2001	J Clin Oncol2001，19，14：	1
12	Liposomal anthracycline treatment for ovarian cancer显示文摘	Markman M Gordon AN McGuire WP	2004	Semin Oncol2004，31，613：	1
13	Doxil study 30 -49 investigators : Long-term surival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian carcinoma显示文摘	Gordon AN Tonda M Sun S	2004	Gynecol Oncol2004，95，：	1
14	CA125-and tumor-specific T-cell responses correlate with prolonged survival in ore-govomab-treated recurrent ovarian cancer patients显示文摘	Gordon AN Schultes BC Gallion H	2004	GynecolOncol2004，94，2：	1
15	Recurrent epithelial ovarian carcinoma:a randomized phase Ⅲ study of pegylated liposomal doxorubicin versus topotecan显示文摘	Gordon AN Fleagle JT Guthrie D	2001	J Clin Oncol2001，19，：	1
16	Recurrent epithelial ovarian carcinoma: a randomized phase study of pegylated liposomal doxorubicin versus topotecan显示文摘	Gordon AN Heagle JT Guthrie D	2001	J Clin Oncol2001，19，14：	1
17	Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer显示文摘	Gordon AN Tonda M Sun S	2004	Gyneccol Oncol2004，95，1：	1
18	Long-term survival ad- vantage for women treated with pegylated liposomal doxo- rubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer 显示文摘	Gordon AN Tonda M Sun S	2004	Gynecol Onco12004，95，1：	1
19	Validation of referral guide- lines for women with pelvic masses显示文摘	Im SS Gordon AN Buttin BM	2005	Obstet Gynecol2005，105，1：	1
20	Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment显示文摘	Andersen AN Witjes H Gordon K	2011	Hum Reprod2011，26，：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示